Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Healthcare Biotechnology
Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Oncolytics Biotech Inc > Turning to Goblet
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(319)
•••
Comment by jimsenioron May 30, 2023 2:20pm
131 Views
Post# 35470755

RE:RE:RE:RE:RE:RE:Turning to Goblet

RE:RE:RE:RE:RE:RE:Turning to Goblet @Q. Thank you for allowing the possibility of synergy. I thought of it while washing the mid-day dishes, and was not sure if an anti-TIGIT and pelareorep could even be a thing. Lay person. Was not sure about TIGIT inhibiting the antiviral response. AI will guide pharma.

I no longer worry about patents as I am trusting that ONC/Y is fully and totally aware that they are getting bought out. To try and go it alone is unrealistic, and partnering is messy to say the least. I could be wrong.

So as a stock holder I am trying to figure out who might be interested and why, when, and how much. That is to say I am anticipating a buyout; anything else and I will be very disappointed. Que sera sera.

I agree time is running out, and expect real clarification in  the few weeks. Cheers.

PS. Washing dishes by hand is an excellent excercise for one's health.
 
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities